- Home
- GCMGW vs SCLXW Comparison
GCMGW vs SCLXW Comparison
Compare GCMGW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMGW
- SCLXW
- Stock Information
- Founded
- GCMGW 1971
- SCLXW N/A
- Country
- GCMGW United States
- SCLXW United States
- Employees
- GCMGW 549
- SCLXW 31
- Industry
- GCMGW Finance/Investors Services
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- GCMGW Finance
- SCLXW Health Care
- Exchange
- GCMGW Nasdaq
- SCLXW Nasdaq
- Market Cap
- GCMGW N/A
- SCLXW N/A
- IPO Year
- GCMGW N/A
- SCLXW N/A
- Fundamental
- Price
- GCMGW $0.22
- SCLXW $0.14
- Analyst Decision
- GCMGW
- SCLXW
- Analyst Count
- GCMGW 0
- SCLXW 0
- Target Price
- GCMGW N/A
- SCLXW N/A
- AVG Volume (30 Days)
- GCMGW 62.4K
- SCLXW 4.0K
- Earning Date
- GCMGW 02-13-2025
- SCLXW 03-07-2025
- Dividend Yield
- GCMGW N/A
- SCLXW N/A
- EPS Growth
- GCMGW N/A
- SCLXW N/A
- EPS
- GCMGW 0.03
- SCLXW N/A
- Revenue
- GCMGW $514,011,999.00
- SCLXW $55,152,000.00
- Revenue This Year
- GCMGW N/A
- SCLXW N/A
- Revenue Next Year
- GCMGW N/A
- SCLXW N/A
- P/E Ratio
- GCMGW $33.02
- SCLXW N/A
- Revenue Growth
- GCMGW 15.79
- SCLXW 22.02
- 52 Week Low
- GCMGW $2.28
- SCLXW $0.18
- 52 Week High
- GCMGW $2.50
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- GCMGW 28.46
- SCLXW 33.86
- Support Level
- GCMGW $0.38
- SCLXW $0.14
- Resistance Level
- GCMGW $0.63
- SCLXW $0.25
- Average True Range (ATR)
- GCMGW 0.12
- SCLXW 0.05
- MACD
- GCMGW -0.12
- SCLXW -0.01
- Stochastic Oscillator
- GCMGW 6.48
- SCLXW 10.79
About GCMGW GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.